Immunotherapy plus chemo before surgery for lung cancer with gene changes
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests adding the immunotherapy drug Adebrelimab to chemotherapy before surgery for people with a type of lung cancer that has certain gene changes. The goal is to see if this combination helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have non-small cell lung cancer that can be surgically removed and has a gene mutation (driver mutation)
- You are in fairly good health (able to do daily activities)
- You have not had any previous cancer treatment like chemotherapy or radiation
- You do not have an autoimmune disease or active infections like HIV or hepatitis
- Your organ function (liver, kidneys, etc.) is adequate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests whether adding new immunotherapy drugs (adebrelimab or retlirafusp alfa plus recaticimab) to standard chemotherapy before lung surgery can help people with resectable non-small cell lung cancer. The goal is to see if this combination improves outcomes for patients whose tumors can be surgically removed.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial combines surgery to remove the main lung tumor with chemo and an immunotherapy drug called sintilimab. It's for people with advanced non-small cell lung cancer that hasn't been treated before and doesn't have certain gene changes.
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
This trial tests whether giving chemotherapy plus immunotherapy before surgery helps people with a specific type of advanced lung cancer. It aims to see if this approach can shrink tumors and make surgery more effective.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.